379 related articles for article (PubMed ID: 29463999)
1. Stimuli-Responsive Nanomedicines for Overcoming Cancer Multidrug Resistance.
Zhou L; Wang H; Li Y
Theranostics; 2018; 8(4):1059-1074. PubMed ID: 29463999
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Approaches of Dual-targeted Nanomedicines for Tumor Multidrug Resistance.
Han W; Shen Z; Zou J; Ye Q; Ge C; Zhao Y; Wang T; Chen Y
Curr Drug Deliv; 2024; 21(2):155-167. PubMed ID: 37143266
[TBL] [Abstract][Full Text] [Related]
3. Drug Resistance in Metastatic Breast Cancer: Tumor Targeted Nanomedicine to the Rescue.
Gote V; Nookala AR; Bolla PK; Pal D
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925129
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in dual- and multi-responsive nanomedicines for precision cancer therapy.
Zhang Y; Li J; Pu K
Biomaterials; 2022 Dec; 291():121906. PubMed ID: 36395660
[TBL] [Abstract][Full Text] [Related]
5. MSN anti-cancer nanomedicines: chemotherapy enhancement, overcoming of drug resistance, and metastasis inhibition.
He Q; Shi J
Adv Mater; 2014 Jan; 26(3):391-411. PubMed ID: 24142549
[TBL] [Abstract][Full Text] [Related]
6. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
Bar-Zeev M; Livney YD; Assaraf YG
Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
[TBL] [Abstract][Full Text] [Related]
7. Overcoming multidrug resistance with nanomedicines.
Ganoth A; Merimi KC; Peer D
Expert Opin Drug Deliv; 2015 Feb; 12(2):223-38. PubMed ID: 25224685
[TBL] [Abstract][Full Text] [Related]
8. Role of integrated cancer nanomedicine in overcoming drug resistance.
Iyer AK; Singh A; Ganta S; Amiji MM
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
[TBL] [Abstract][Full Text] [Related]
9. Reversal of multidrug resistance by stimuli-responsive drug delivery systems for therapy of tumor.
Yin Q; Shen J; Zhang Z; Yu H; Li Y
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1699-715. PubMed ID: 23611952
[TBL] [Abstract][Full Text] [Related]
10. Anticancer nanomedicines harnessing tumor microenvironmental components.
Li Y; Chen Z; Gu L; Duan Z; Pan D; Xu Z; Gong Q; Li Y; Zhu H; Luo K
Expert Opin Drug Deliv; 2022 Apr; 19(4):337-354. PubMed ID: 35244503
[TBL] [Abstract][Full Text] [Related]
11. Nanocarriers overcoming biological barriers induced by multidrug resistance of chemotherapeutics in 2D and 3D cancer models.
Petrikaite V; D'Avanzo N; Celia C; Fresta M
Drug Resist Updat; 2023 May; 68():100956. PubMed ID: 36958083
[TBL] [Abstract][Full Text] [Related]
12. P-glycoprotein-targeted photodynamic therapy boosts cancer nanomedicine by priming tumor microenvironment.
Mao C; Li F; Zhao Y; Debinski W; Ming X
Theranostics; 2018; 8(22):6274-6290. PubMed ID: 30613297
[TBL] [Abstract][Full Text] [Related]
13. Nanomedicines for advanced cancer treatments: Transitioning towards responsive systems.
van Elk M; Murphy BP; Eufrásio-da-Silva T; O'Reilly DP; Vermonden T; Hennink WE; Duffy GP; Ruiz-Hernández E
Int J Pharm; 2016 Dec; 515(1-2):132-164. PubMed ID: 27725268
[TBL] [Abstract][Full Text] [Related]
14. Nanomedicine to Deal With Cancer Cell Biology in Multi-Drug Resistance.
Tekchandani P; Kurmi BD; Paliwal SR
Mini Rev Med Chem; 2017; 17(18):1793-1810. PubMed ID: 26891930
[TBL] [Abstract][Full Text] [Related]
15. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
Shapira A; Livney YD; Broxterman HJ; Assaraf YG
Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
[TBL] [Abstract][Full Text] [Related]
16. Surface-Engineered Cancer Nanomedicine: Rational Design and Recent Progress.
Ahmad J; Ameeduzzafar ; Ahmad MZ; Akhter H
Curr Pharm Des; 2020; 26(11):1181-1190. PubMed ID: 32056517
[TBL] [Abstract][Full Text] [Related]
17. Nanomedicine solutions to intricate physiological-pathological barriers and molecular mechanisms of tumor multidrug resistance.
Li Y; Xu X
J Control Release; 2020 Jul; 323():483-501. PubMed ID: 32387548
[TBL] [Abstract][Full Text] [Related]
18. Nanoparticle approaches to combating drug resistance.
Moon JH; Moxley JW; Zhang P; Cui H
Future Med Chem; 2015 Aug; 7(12):1503-10. PubMed ID: 26334205
[TBL] [Abstract][Full Text] [Related]
19. Polysaccharide-Based Stimulus-Responsive Nanomedicines for Combination Cancer Immunotherapy.
Li Q; Liu X; Yan C; Zhao B; Zhao Y; Yang L; Shi M; Yu H; Li X; Luo K
Small; 2023 Jun; 19(23):e2206211. PubMed ID: 36890780
[TBL] [Abstract][Full Text] [Related]
20. Computer-assisted engineering of programmed drug releasing multilayer nanomedicine via indomethacin-mediated ternary complex for therapy against a multidrug resistant tumor.
Che L; Liu Z; Wang D; Xu C; Zhang C; Meng J; Zheng J; Yuan H; Zhao G; Zhou X
Acta Biomater; 2019 Oct; 97():461-473. PubMed ID: 31344512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
